BMS 954561

Drug Profile

BMS 954561

Alternative Names: BMS-954561

Latest Information Update: 28 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Analgesics
  • Mechanism of Action GABA receptor modulators; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Postherpetic neuralgia

Most Recent Events

  • 25 Oct 2011 Bristol-Myers Squibb completes enrolment in its phase II trial for Postherpetic neuralgia in US and France (NCT01305538)
  • 28 Apr 2011 Phase-II clinical trials in Diabetic neuropathies in USA (PO)
  • 07 Apr 2011 Phase-II clinical trials in Postherpetic neuralgia in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top